Issue Fragmented approval rules and unsettled strain ownership sit under the transition

Summary

The Dubai Future Foundation outlook points to two institutional gaps underneath the move to precision fermentation. First, approval pathways outside the United States and European Union remain fragmented. That slows commercialization in exactly the markets where geographic advantages such as cheap clean energy may be strongest. Second, questions over foundational biological intellectual property are still unsettled, including who owns engineered strains and under what licensing terms. The outlook adds that proving a fermentation process at commercial scale needs capital in the gap between venture funding and infrastructure investment. Some companies are bridging that gap by repurposing idle pharmaceutical and industrial fermentation capacity, but financing, regulation and intellectual property would all need to adapt.